On July 22, JD Health (06618.HK) fell 3.15% in regular trading, trading at 37.48 HKD/share, with turnover of approximately 76.93 million HKD.

On the news front, renowned fund manager Zhang Kun's Q2 report, disclosed on July 21, revealed that JD Health was removed from the top ten holdings of his flagship product E Fund Blue Chip Select. The fund underwent a significant portfolio restructuring after adding two co-managers in May, shifting away from consumer and healthcare stocks toward semiconductor and AI hardware names such as SMIC and Dongshan Precision. JD Health also exited the top holdings of E Fund Quality Enterprise Three-Year. The fund's overall Hong Kong stock exposure was cut by nearly half during Q2, with the concentrated institutional selling weighing on short-term market sentiment.

Despite the selling pressure, Goldman Sachs on the same day maintained a Buy rating on JD Health with a target price of 65 HKD, forecasting Q2 revenue growth of 18% year-over-year and an adjusted operating margin of 7.1%, representing continued improvement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)